Targets › CYP2C19
1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Mar 2027.
A cytochrome P450 monooxygenase involved in the metabolism of polyunsaturated fatty acids (PUFA). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase). (UniProt, P33261)
Open in Phaseline: the race on CYP2C19, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| The University of Queensland | voriconazole Cytochrome P450 51 inhibitor | CYP2C19 | Phase 2 | Fungal Infection | Mar 2027 |
Fungal Infection (1)
–
The University of Queensland (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.